文献速递其他结缔组织病

多发性肌炎是否仍然存在?三级肌炎中心的回顾性诊断复核

Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究对英国三级肌炎门诊255例特发性炎症性肌病(IIM)患者中按EULAR/ACR标准及专家意见分类为多发性肌炎(PM)的37例进行回顾性复核,最终仅9例(24.3%)仍归类为PM,占原队列3.5%,主要替代诊断为免疫介导坏死性肌病和结缔组织病重叠肌炎。建议通过全面检查、完整肌炎自身抗体谱和仔细解读活检结果来确认正确的IIM亚型。

要点

  • 按EULAR/ACR标准及专家意见分类的PM中仅24.3%最终仍为PM,占原队列3.5%。
  • 主要替代诊断为免疫介导坏死性肌病(13.5%)和结缔组织病重叠肌炎(19%)。
  • 建议全面检查、完整肌炎自身抗体谱及仔细解读活检以确认IIM亚型。

核心结论

  • PM现在可被视为罕见的IIM亚组,多数既往分类为PM的患者可归入其他诊断。

研究设计与样本

  • 来自英国三级肌炎门诊既往报道的255例IIM患者队列,其中37例按EULAR/ACR IIM标准及专家意见分类为PM,进行回顾性临床数据和辅助检查复核并达成共识最终分类。

主要发现

  • 9/37(24.3%)仍归类为PM,占原队列3.5%,这些PM患者肌炎抗体血清学阴性且对免疫抑制治疗有反应。
  • 行肌肉活检的7例PM中4例(57.1%)显示HLA-1上调及肌内膜炎症浸润。
  • 免疫介导坏死性肌病5/37(13.5%)和结缔组织病重叠肌炎7/37(19%)是主要替代诊断。
  • 其余诊断为未分类肌病6/37(16%)、皮肌炎2/37(5%)、肿瘤相关肌病3/37(8.1%)和非炎性肌病1/37(3%,肌原纤维肌病)。
  • 4/37(10%)因数据不足无法自信重新分类。

关键数值与推荐

  • PM最终分类比例:9/37(24.3%),占原队列255例的3.5%。
  • 免疫介导坏死性肌病5/37(13.5%),结缔组织病重叠肌炎7/37(19%)。
  • 行肌肉活检的PM患者中HLA-1上调及肌内膜炎症浸润4/7(57.1%)。

临床怎么用

  • 对拟诊PM的患者应进行全面检查、完整肌炎自身抗体谱检测并仔细解读肌肉活检结果以确认正确IIM亚型。

局限性

  • 为单中心回顾性研究,4/37(10%)患者因数据不足无法自信重新分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The current classification criteria for idiopathic inflammatory myopathy (IIM) retain PM as a major disease subgroup. However, evolution in the understanding of IIM has suggested that many of these patients could be better described as having an alternative diagnosis. In the present study, we apply the latest understanding of IIM subtyping to retrospectively review PM diagnoses in a large cohort of IIM patients. METHODS: Within a previously reported cohort of 255 patients from a UK tertiary myositis clinic, 37 patients classified as PM according to both the EULAR/ACR IIM criteria and expert opinion were identified. Clinical data and complementary tests were reviewed, and consensus decisions regarding final classification were reached in each case. RESULTS: Nine (9/37, 24.3%) patients remained classified as PM, 3.5% (9/255) of the original cohort; these PM patients were seronegative for myositis antibodies, responsive to immunosuppression, and in 4/7 (57.1%) patients where muscle biopsy was performed had HLA-1 upregulation and endomysial inflammatory infiltrates. Immune-mediated necrotizing myopathy (5/37, 13.5%) and connective tissue disease overlap myositis (7/37, 19%) were the main alternative diagnoses. The remaining patients were diagnosed as: unspecified myopathy (6/37, 16%), dermatomyositis (2/37, 5%), cancer-associated myopathy (3/37, 8.1%), and non-inflammatory myopathy (1/37, 3%, myofibrillar myopathy). Four patients (4/37, 10%) had insufficient data available to confidently reclassify. CONCLUSION: Our study confirms that PM can now be considered a rare IIM subgroup. A thorough examination, complete myositis autoantibody panel, and careful interpretation of the biopsy results is recommended to confirm the correct IIM sub-type.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Loarce-Martos J, Lilleker JB, Parker M, et al. Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. Rheumatology (Oxford). 2021. PMID: 33367878. doi:10.1093/rheumatology/keaa801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。